Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 5, No. 3-4, 2008
Issue release date: March 2008
Section title: Alpha-Synuclein
Free Access
Neurodegenerative Dis 2008;5:222–224

Leucine-Rich Repeat Kinase 2 Colocalizes with α-Synuclein in Parkinson’s Disease, but Not Tau-Containing Deposits in Tauopathies

Perry G.a, b · Zhu X.a · Babar A.K.a · Siedlak S.L.a · Yang Q.a · Ito G.c · Iwatsubo T.c · Smith M.A.a · Chen S.G.a
aDepartment of Pathology, Case Western Reserve University, Cleveland, Ohio, and bCollege of Sciences, The University of Texas at San Antonio, San Antonio, Tex., USA; cDepartment of Neuropathology and Neuroscience, University of Tokyo, Tokyo, Japan
email Corresponding Author

George Perry, PhD

College of Sciences, University of Texas at San Antonio

One USTA Circle

San Antonio, TX 78249 (USA)

Tel. +1 210 458 4450, Fax +1 210 458 4445, E-Mail george.perry@utsa.edu


  1. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A: Genetics of Parkinson’s disease and parkinsonism. Ann Neurol 2006;60:389–398.
  2. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: Alpha-synuclein in Lewy bodies. Nature 1997;388:839–840.
  3. Zhu X, Babar A, Siedlak SL, Yang Q, Ito G, Iwatsubo T, Smith MA, Perry G, Chen SG: LRRK2 in Parkinson’s disease and dementia with Lewy bodies. Mol Neurodegener 2006;1:17.
    External Resources
  4. Zhu X, Siedlak SL, Smith MA, Perry G, Chen SG: LRRK2 protein is a component of Lewy bodies. Ann Neurol 2006;60:617–618; author reply 618–619.
  5. Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, Van Deerlin VM: Biochemical and pathological characterization of Lrrk2. Ann Neurol 2006;59:315–322.
  6. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, Ahmad R, Miller DW, Kesavapany S, Singleton A, Lees A, Harvey RJ, Harvey K, Cookson MR: Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006;23:329–341.
  7. Miklossy J, Arai T, Guo JP, Klegeris A, Yu S, McGeer EG, McGeer PL: LRRK2 expression in normal and pathologic human brain and in human cell lines. J Neuropathol Exp Neurol 2006;65:953–963.
  8. Hatano T, Kubo SI, Imai S, Maeda M, Ishikawa K, Mizuno Y, Hattori N: Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet 2007;16:678–690.
  9. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM: Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 2005;102:16842–16847.
  10. Iwatsubo T: Aggregation of alpha-synuclein in the pathogenesis of Parkinson’s disease. J Neurol 2003;250(suppl 3):III11–III14.